173 related articles for article (PubMed ID: 26102031)
1. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells.
Zhang Y; Li D; Zhao X; Song S; Zhang L; Zhu D; Wang Z; Chen X; Zhou J
Biochem Biophys Res Commun; 2015 Aug; 463(4):1144-51. PubMed ID: 26102031
[TBL] [Abstract][Full Text] [Related]
2. Silencing of decoy receptor 3 (DcR3) expression by siRNA in pancreatic carcinoma cells induces Fas ligand-mediated apoptosis in vitro and in vivo.
Zhou J; Song S; He S; Wang Z; Zhang B; Li D; Zhu D
Int J Mol Med; 2013 Sep; 32(3):653-60. PubMed ID: 23846297
[TBL] [Abstract][Full Text] [Related]
3. Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway.
Chen PH; Yang CR
J Immunol; 2008 Dec; 181(12):8441-9. PubMed ID: 19050262
[TBL] [Abstract][Full Text] [Related]
4. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.
Tsuji S; Hosotani R; Yonehara S; Masui T; Tulachan SS; Nakajima S; Kobayashi H; Koizumi M; Toyoda E; Ito D; Kami K; Mori T; Fujimoto K; Doi R; Imamura M
Int J Cancer; 2003 Aug; 106(1):17-25. PubMed ID: 12794752
[TBL] [Abstract][Full Text] [Related]
5. Idiopathic pulmonary fibrosis fibroblasts become resistant to Fas ligand-dependent apoptosis via the alteration of decoy receptor 3.
Im J; Kim K; Hergert P; Nho RS
J Pathol; 2016 Sep; 240(1):25-37. PubMed ID: 27218286
[TBL] [Abstract][Full Text] [Related]
6. Correlation between expression of DcR3 on tumor cells and sensitivity to FasL.
Li W; Zhang C; Chen C; Zhuang G
Cell Mol Immunol; 2007 Dec; 4(6):455-60. PubMed ID: 18163957
[TBL] [Abstract][Full Text] [Related]
7. Dcr3 inhibit p53-dependent apoptosis in gamma-irradiated lung cancer cells.
Sung HY; Wu HG; Ahn JH; Park WY
Int J Radiat Biol; 2010 Sep; 86(9):780-90. PubMed ID: 20597837
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment with denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells.
Yang CR; Guh JH; Teng CM; Chen CC; Chen PH
Br J Pharmacol; 2009 Aug; 157(7):1175-85. PubMed ID: 19466993
[TBL] [Abstract][Full Text] [Related]
9. 'Decoy' and 'non-decoy' functions of DcR3 promote malignant potential in human malignant fibrous histiocytoma cells.
Toda M; Kawamoto T; Ueha T; Kishimoto K; Hara H; Fukase N; Onishi Y; Harada R; Minoda M; Kurosaka M; Akisue T
Int J Oncol; 2013 Sep; 43(3):703-12. PubMed ID: 23817777
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.
Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y
Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580
[TBL] [Abstract][Full Text] [Related]
11. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer.
Lin WW; Hsieh SL
Biochem Pharmacol; 2011 Apr; 81(7):838-47. PubMed ID: 21295012
[TBL] [Abstract][Full Text] [Related]
12. Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development.
Chen C; Zhang C; Zhuang G; Luo H; Su J; Yin P; Wang J
Cancer Invest; 2008 Dec; 26(10):965-74. PubMed ID: 19093253
[TBL] [Abstract][Full Text] [Related]
13. Functional characterisation of decoy receptor 3 in Crohn's disease.
Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
[TBL] [Abstract][Full Text] [Related]
14. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis.
Hayashi S; Miura Y; Nishiyama T; Mitani M; Tateishi K; Sakai Y; Hashiramoto A; Kurosaka M; Shiozawa S; Doita M
Arthritis Rheum; 2007 Apr; 56(4):1067-75. PubMed ID: 17393415
[TBL] [Abstract][Full Text] [Related]
15. Decoy receptor 3 regulates the expression of various genes in rheumatoid arthritis synovial fibroblasts.
Fukuda K; Miura Y; Maeda T; Takahashi M; Hayashi S; Kurosaka M
Int J Mol Med; 2013 Oct; 32(4):910-6. PubMed ID: 23912906
[TBL] [Abstract][Full Text] [Related]
16. Expressions of Fas/DcR3 and RGD-FasL mediated apoptosis in pituitary adenomas.
Chen L; Tian X; Li W; Agarwal A; Zhuang G
Neurol India; 2009; 57(1):28-30. PubMed ID: 19305072
[TBL] [Abstract][Full Text] [Related]
17. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.
Connor JP; Felder M
Gynecol Oncol; 2008 Nov; 111(2):330-5. PubMed ID: 18723214
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of decoy receptor 3 in human breast cancer: relevance to lymphangiogenesis.
Wu Q; Zheng Y; Chen D; Li X; Lu C; Zhang Z
J Surg Res; 2014 May; 188(2):459-65. PubMed ID: 24612949
[TBL] [Abstract][Full Text] [Related]
19. Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer.
Wang W; Zhang M; Sun W; Yang S; Su Y; Zhang H; Liu C; Li X; Lin L; Kim S; Okunieff P; Zhang Z; Zhang L
PLoS One; 2013; 8(10):e74272. PubMed ID: 24204567
[TBL] [Abstract][Full Text] [Related]
20. Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3.
Liu W; Ramagopal U; Cheng H; Bonanno JB; Toro R; Bhosle R; Zhan C; Almo SC
Structure; 2016 Nov; 24(11):2016-2023. PubMed ID: 27806260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
